EMA grants orphan drug designation to Enterprise Therapeutics’ ETD001 inhaled ENaC blocker for CF

Enterprise Therapeutics announced that the EMA has granted orphan drug designation to the company’s ETD001 inhaled epithelial sodium channel for the treatment of cystic fibrosis. Earlier this year, the company announced that a Phase 2 trial of ETD001 in CF patients had met its primary endpoint. According to Enterprise’s web site, the company’s pipeline includes a dry powder formulation of an ENaC blocker for inhalation in addition to the nebulized ETD001 that is in Phase 2 development.

Enterprise Therapeutics CEO John Ford commented, “Orphan drug designation represents an important regulatory milestone for the ETD001 programme and for Enterprise Therapeutics. The decision by the EMA reflects the continued need for additional treatment options for people with cystic fibrosis, particularly those who are not able to benefit from CFTR modulators. We look forward to continuing the development of ETD001 in CF as well as other mucus congestion related respiratory diseases.”

Head of Regulatory Affairs Annabella Amatulli said, “Our regulatory strategy supports our global development plan for ETD001, aligned with our goal to provide improved therapeutic options for people with cystic fibrosis. The EMA’s orphan drug designation further validates the strength of the program’s scientific rationale and outcomes of the Phase 2 clinical trial.”

Read the Enterprise Therapeutics press release

Share

published on

December 9-December 11: DDL 2026, Edinburgh, Scotland

April 27-30: RDD Europe 2027, Antibes, France

May 30-June 2: ISAM Congress 2027, Dublin, Ireland

June 23: SMI London, London, UK